Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William A Richards

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Review of Psychiatry (Abingdon, England)|November 14, 2018
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventionsAlbert Garcia-Romeu, William A Richards
Psychopharmacology|June 16, 2011
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsRoland R Griffiths, Matthew W Johnson, William A Richards, et al.
Journal of Psychopharmacology (Oxford, England)|April 1, 2025
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsTomislav Majić, Timo Torsten Schmidt, Anna Gröticke, et al.
Psychedelic Medicine (New Rochelle, N.Y.)|March 23, 2026
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World ReligionsRoland R Griffiths, Robert Jesse, William A Richards, et al.
Journal of Psychopharmacology (Oxford, England)|December 3, 2016
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialRoland R Griffiths, Matthew W Johnson, Michael A Carducci, et al.
International Journal of Methods in Psychiatric Research|April 26, 2026
Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsKurt Stocker, Matthias Hartmann, Frederick S Barrett, et al.
Journal of Psychopharmacology (Oxford, England)|October 13, 2017
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviorsRoland R Griffiths, Matthew W Johnson, William A Richards, et al.
Frontiers in Psychiatry|March 1, 2021
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical ResearchSara J Tai, Elizabeth M Nielson, Molly Lennard-Jones, et al.
Journal of Palliative Medicine|March 14, 2022
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious IllnessWilliam E Rosa, Zachary Sager, Megan Miller, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Review of Psychiatry (Abingdon, England)|November 14, 2018
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventionsAlbert Garcia-Romeu, William A Richards
Psychopharmacology|June 16, 2011
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsRoland R Griffiths, Matthew W Johnson, William A Richards, et al.
Journal of Psychopharmacology (Oxford, England)|April 1, 2025
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsTomislav Majić, Timo Torsten Schmidt, Anna Gröticke, et al.
Psychedelic Medicine (New Rochelle, N.Y.)|March 23, 2026
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World ReligionsRoland R Griffiths, Robert Jesse, William A Richards, et al.
Journal of Psychopharmacology (Oxford, England)|December 3, 2016
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialRoland R Griffiths, Matthew W Johnson, Michael A Carducci, et al.
International Journal of Methods in Psychiatric Research|April 26, 2026
Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsKurt Stocker, Matthias Hartmann, Frederick S Barrett, et al.
Journal of Psychopharmacology (Oxford, England)|October 13, 2017
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviorsRoland R Griffiths, Matthew W Johnson, William A Richards, et al.
Frontiers in Psychiatry|March 1, 2021
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical ResearchSara J Tai, Elizabeth M Nielson, Molly Lennard-Jones, et al.
Journal of Palliative Medicine|March 14, 2022
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious IllnessWilliam E Rosa, Zachary Sager, Megan Miller, et al.
Pageof 1